Over 100 billion birds vaccinated with VAXXITEK Over 100 billion birds vaccinated with VAXXITEK Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences Option to Acquire Trutino Biosciences
Mental health: a $1 trillion burden demanding policy action Mental health: a $1 trillion burden demanding policy action Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Phase 1 start for novel triple agonist obesity treatment Phase 1 start for novel triple agonist obesity treatment Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Management Systems Management Systems Suppliers shall use management systems to support continuous improvement and compliance with the Supplier Code of Conduct.
Moving towards a rabies-free Southeast Asia Moving towards a rabies-free Southeast Asia Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Eugene Zalmover Eugene Zalmover Learn how Eugene’s work paved the way for digital innovation in Patient Safety.
“My ultimate goal is to cure cancer” “My ultimate goal is to cure cancer” Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
Innovation Prize Winners Innovation Prize Winners Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
Biotherapeutics Discovery Biotherapeutics Discovery We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
World Rabies Day 2020 sustainable dog vaccination World Rabies Day 2020 sustainable dog vaccination World Rabies Day 2020 sustainable dog vaccination
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Positive-CHMP-opinion-for-dabigatran-in-children Positive-CHMP-opinion-for-dabigatran-in-children Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
Distributing medicine globally with pharmaceutical logistics Distributing medicine globally with pharmaceutical logistics From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
Genomic Lens Linking Worlds in DNA Genomic Lens Linking Worlds in DNA Adding a new dimension to drug discovery with the help of data science and DNA
biopharmaceuticals-in-china biopharmaceuticals-in-china Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Career tips from our Global Head of HR Career tips from our Global Head of HR Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
S&P Animal Health Partnering Oct 2023 S&P Animal Health Partnering Oct 2023 Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients